FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of August 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F X Form 40 - F
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes ______ No X
This Form 6-K consists of:
A press release issued by Vasogen Inc. on August 1, 2000, entitled: "Vasogen
Appoints Tamar Howson as Director of Business Development"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By
---------------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: August 1, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com tel: (905) 569-9065
e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Appoints Tamar Howson as Director of Business Development
Toronto, Ontario, (August 1, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is
pleased to announced the appointment of Ms. Tamar Howson to the position of
Director of Business Development. Ms. Howson will be responsible for directing
the Company's licensing and corporate partnering initiatives. She brings
extensive licensing and business development experience to Vasogen, recently
holding the position of Senior Vice-President and Director of Worldwide Business
Development at SmithKline Beecham, a leading healthcare company.
Ms. Howson joined SmithKline as Vice-President and Director, Worldwide Business
Development in 1991. Her responsibilities included the in-licensing and business
development activities at SmithKline and S.R. One Limited. Prior to joining
SmithKline, Ms. Howson served as Vice-President, Venture Investments at Johnson
Associates, a venture capital firm. She has also held the position of Director
of Worldwide Business Development and Licensing for Squibb Corporation and has
ten years' experience with FMC Corporation and Envirotech Corporation, where she
was responsible for business planning, venture analysis, and project management.
Ms. Howson holds an MBA in Finance and International Business from Columbia
University, an MSc from City College of New York, and a BSc in Chemical
Engineering from Technion in Israel.
"Ms. Howson brings to Vasogen extensive experience in the area of licensing and
business development," commented Bill Grant, Vice-Chairman of Vasogen's Board of
Directors and past long-time Director of SmithKline Beecham. "With an impressive
record of successful licensing transactions, Tamar has established a worldwide
network of pharmaceutical and healthcare industry contacts."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
